In the last trading session, 1.3 million Contineum Therapeutics Inc (NASDAQ:CTNM) shares changed hands as the company’s beta touched 0.78. With the company’s per share price at $4.11 changed hands at $0.1 or 2.49% during last session, the market valuation stood at $106.33M. CTNM’s last price was a discount, traded about -435.28% off its 52-week high of $22.00. The share price had its 52-week low at $3.35, which suggests the last value was 18.49% up since then. When we look at Contineum Therapeutics Inc’s average trading volume, we note the 10-day average is 0.29 million shares, with the 3-month average coming to 110.15K.
Analysts gave the Contineum Therapeutics Inc (CTNM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CTNM as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Contineum Therapeutics Inc (NASDAQ:CTNM) trade information
Instantly CTNM was in green as seen at the end of in last trading. With action -13.66%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -79.38%, with the 5-day performance at -13.66% in the red. However, in the 30-day time frame, Contineum Therapeutics Inc (NASDAQ:CTNM) is 20.88% up. Looking at the short shares, we see there were 0.77 million shares sold at short interest cover period of 6.13 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 74.31% from its current market value. According to analyst projections, CTNM’s forecast low is 16 with 16 as the target high. To hit the forecast high, the stock’s price needs a -289.29% plunge from its current level, while the stock would need to soar -289.29% for it to hit the projected low.
The 2025 estimates are for Contineum Therapeutics Inc earnings to decrease by -7.73%, but the outlook for the next 5-year period is at -8.65% per year.
CTNM Dividends
Contineum Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-14.
Contineum Therapeutics Inc (NASDAQ:CTNM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.82% of Contineum Therapeutics Inc shares while 79.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 81.47%. There are 79.99% institutions holding the Contineum Therapeutics Inc stock share, with SUVRETTA CAPITAL MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 7.9824% of the shares, roughly 2.05 million CTNM shares worth $36.16 million.
JOHNSON & JOHNSON holds the second largest percentage of outstanding shares, with 7.6941% or 1.98 million shares worth $34.85 million as of 2024-06-30.
